{"id":"W3087285392","doi":"10.1371/journal.pmed.1003222","title":"Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study","year":2020,"lang":"en","type":"article","venue":"PLoS Medicine","topic":"Muscle Physiology and Disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":82,"is_retracted":false,"has_abstract":true,"ca_institutions":"Alberta Children's Hospital","funders":"National Institute of Child Health and Human Development; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Parent Project Muscular Dystrophy; National Institute of Neurological Disorders and Stroke; National Institutes of Health; Astellas Pharma; Eunice Kennedy Shriver National Institute of Child Health and Human Development; European Commission; PTC Therapeutics; Sarepta Therapeutics; FibroGen; Pfizer; National Institute on Disability and Rehabilitation Research; National Institute on Disability, Independent Living, and Rehabilitation Research; Eli Lilly and Company","keywords":"Duchenne muscular dystrophy; Interim analysis; Interim; Medicine; Muscular dystrophy; Randomized controlled trial; Physical therapy; Physical medicine and rehabilitation; Internal medicine; Political science","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004358676,0.0001515779,0.001043913,0.000108017,0.000023426,0.000002187223,0.0002271161,0.0000833241,0.00004959888],"category_scores_gemma":[0.0006034452,0.0001141363,0.00005166388,0.0003364645,0.0003283805,0.000006270013,0.0001936483,0.00009202675,2.698637e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000003457761,"about_ca_system_score_gemma":0.0000237374,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000332372,"about_ca_topic_score_gemma":0.00008997166,"domain_scores_codex":[0.9985752,0.0002771599,0.000491643,0.000407438,0.0001182851,0.0001303489],"domain_scores_gemma":[0.9992092,0.00006304423,0.0001868786,0.0003482765,0.00009078408,0.000101797],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.08539392,0.001777192,0.002459771,0.00005427943,0.00150648,0.000007762033,0.00155681,0.000178149,0.9063823,0.000006773025,0.00003636881,0.0006402105],"study_design_scores_gemma":[0.6475739,0.02417241,0.2647605,0.0002395335,0.006270358,0.000001852632,0.004206881,0.02563337,0.02645763,0.00007234905,0.00005065148,0.0005605771],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.997691,0.0007267877,0.000332284,0.0003161178,0.00001984887,0.0008193762,0.000008319119,0.000003620494,0.00008269048],"genre_scores_gemma":[0.9990985,0.0002179343,0.0001832469,0.0002681057,0.0000383214,0.00002586827,0.0001527166,0.00001092212,0.000004422831],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8799247,"threshold_uncertainty_score":0.4654344,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04221909287974521,"score_gpt":0.3289326659827698,"score_spread":0.2867135731030246,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}